ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > TSE LISTING

<< Previous

Bullboard Posts

Next >>

Post by goldtechon Aug 16, 2023 12:55pm

214 Views

Post# 35591233

TSE LISTING

Now it shows the acumen of this management team. Going off the TSE and spending millions acquiring a new CEO that has done nothing and keeping this lame board has cost the shareholders their longtime dreams of having a cure for AD. All time lows for PMN and you say what best in class. Worst management team ever and the greedy will prevail.

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment